证券代码：300723 证券简称：一品红 公告编号：2024-083 非诺贝特酸胆碱缓释胶囊属贝特类血脂调节药，通过抑制极低密度脂蛋白胆 药品 名称 药品分 类代码 药品 分类 医保 分类 编 号 支付标准 备注 协议有 效期 非诺 贝特 酸胆 碱缓 释胶 囊 XC10AB 调节 血脂 药 医保 乙类 9 1.36 元(45mg(按 C₁₇ H₁₅ ClO₄ 计)/粒)； 3.15 元(135mg(按 C₁₇H₁₅ClO₄计)/ 粒) 限：成人控制饮食 基础上：1.降低重 度高甘油三酯血症 患者甘油三酯(TG) 水平；2.原发性高 胆固醇血症或混合 型血脂异常患者的 治疗。 2025 年 1 月 1 日 至 2026 年 12 月 31 日 一、药品的基本情况 一品红药业股份有限公司 关于全资子公司产品非诺贝特酸胆碱缓释胶囊被纳入国家医保目录的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据国家医保局、人力资源和社会保障部发布《关于印发<国家基本医疗保 险、工伤保险和生育保险药品目录(2024 年)>的通知》（医保发[2024]33 号，以 下简称" ...

证券代码：300723 证券简称：一品红 公告编号：2024-082 一品红药业股份有限公司 关于控股子公司四价流感重组蛋白疫苗获得临床试验批准的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，一品红药业股份有限公司（以下简称"公司"）控股子公司广东华南 疫苗股份有限公司（以下简称"华南疫苗"）自主研发的四价流感重组蛋白疫苗 的药物临床试验申请获得国家药品监督管理局批准，并收到《药物临床试验批准 通知书》（通知书编号：2024LP02496），同意开展预防流行性感冒的临床试验， 现将相关情况公告如下： 一、《药物临床试验批准通知书》主要内容 1．药品名称：四价流感重组蛋白疫苗 2．受理号：CXSL2400528 3．药品类型：预防用生物制品 药品研发具有高投入、高风险、高收益的特点，从临床试验到投产上市的周 期长、环节多，易受到诸多不可预测的因素影响，临床试验进度及结果、未来产 品市场竞争形势均存在诸多不确定性。 4．注册分类：1.3 5．审批结论：根据《中华人民共和国药品管理法》、《中华人民共和国疫 苗管理法》及有关规定，经审查，2024 年 8 ...

Financial Performance - Revenue for Q3 2024 was RMB 327.3 million, a decrease of 43.97% year-over-year[2] - Net profit attributable to shareholders for Q3 2024 was RMB -293.0 million, a decrease of 480.43% year-over-year[2] - Total revenue for the first three quarters of 2024 was RMB 1.24 billion, a decrease of 32.98% year-over-year[5] - Net profit attributable to shareholders for the first three quarters of 2024 was RMB -246.5 million, a decrease of 187.44% year-over-year[5] - Total revenue for the first three quarters of 2024 was 1,239,822,567.52 RMB, a decrease of 33.0% compared to the same period last year[27] - Operating profit for the first three quarters of 2024 was 9,145,461.83 RMB, a significant decrease of 96.6% compared to the same period last year[28] - Net profit for the first three quarters of 2024 was -269,444,690.23 RMB, a sharp decline of 203.9% compared to the same period last year[28] - Comprehensive income for the period totaled -269,444,690.23 yuan, with a net loss attributable to the parent company of -246,538,981.96 yuan[29] - Basic and diluted earnings per share were both -0.5458 yuan[29] Cash Flow and Liquidity - Cash flow from operating activities for the first three quarters of 2024 was RMB -213.0 million, a decrease of 182.91% year-over-year[2] - Cash received from selling goods and providing services decreased by 20.60% to 1,516,044,196.06 yuan, primarily due to lower sales revenue[8] - Cash received from tax refunds increased by 39.63% to 10,907,633.49 yuan, driven by increased VAT refunds from equipment purchases[8] - Cash received from other operating activities decreased by 71.55% to 31,269,862.25 yuan, mainly due to reduced government subsidies and deposits[8] - Cash paid for goods and services increased by 44.80% to 416,378,189.95 yuan, primarily due to higher trade business procurement payments[8] - Cash received from investments surged by 209.35% to 1,608,871,813.69 yuan, mainly due to increased short-term financial product purchases[9] - Cash received from financing activities increased by 81.05% to 1,720,000,000.00 yuan, driven by higher bank borrowings[9] - Net cash flow from operating activities was -212,955,900.57 yuan, compared to 256,852,112.02 yuan in the previous period[30] - Net cash flow from investing activities was -351,374,829.87 yuan, an improvement from -564,657,590.78 yuan in the previous period[31] - Net cash flow from financing activities was 765,129,526.79 yuan, compared to 223,919,396.11 yuan in the previous period[31] - Net increase in cash and cash equivalents was 201,096,079.58 yuan, a significant improvement from -83,886,082.65 yuan in the previous period[31] - The ending balance of cash and cash equivalents was 608,610,630.40 yuan, up from 561,709,670.34 yuan in the previous period[31] Assets and Liabilities - Total assets as of September 30, 2024, were RMB 4.57 billion, an increase of 3.73% compared to the end of the previous year[2] - Shareholders' equity as of September 30, 2024, was RMB 2.18 billion, a decrease of 13.51% compared to the end of the previous year[2] - Short-term borrowings increased by 72.73% to RMB 950.0 million as of September 30, 2024, compared to the beginning of the year[5] - Long-term borrowings increased by 343.75% to RMB 710.0 million as of September 30, 2024, compared to the beginning of the year[7] - Total assets as of the end of Q3 2024 were 4,569,626,117.65 RMB, an increase of 3.7% compared to the end of 2023[25] - Total liabilities as of the end of Q3 2024 were 2,335,444,779.79 RMB, an increase of 29.2% compared to the end of 2023[26] - Short-term borrowings as of the end of Q3 2024 were 950,000,000 RMB, an increase of 72.7% compared to the end of 2023[25] - Long-term borrowings as of the end of Q3 2024 were 710,000,000 RMB, an increase of 343.8% compared to the end of 2023[25] - Fixed assets as of the end of Q3 2024 were 1,459,596,678.54 RMB, a decrease of 8.1% compared to the end of 2023[25] - Construction in progress as of the end of Q3 2024 was 315,941,955.47 RMB, an increase of 92.6% compared to the end of 2023[25] R&D and Innovation - R&D expenses increased by 13.64% to 200,742,786.69 yuan, reflecting the company's continued investment in R&D projects[8] - R&D expenses for the first three quarters of 2024 were 200,742,786.69 RMB, an increase of 13.6% compared to the same period last year[27] - The company's self-developed projects have obtained 6 drug registration certificates (including raw material drug filing registration numbers) as of the disclosure date[16] - The wholly-owned subsidiary's innovative drug APH01727 tablets received clinical trial registration acceptance on May 14, 2024[17] - The wholly-owned subsidiary's innovative drug APH01727 tablets received clinical trial approval on July 24, 2024[18] Shareholder and Equity Information - The company repurchased and canceled 1,850,515 restricted shares from 92 incentive objects under the second phase of the restricted stock incentive plan[13] - The company repurchased and canceled 600,000 restricted shares from 1 incentive object under the 2022 stock option and restricted stock incentive plan[14] - The company's top 10 shareholders include Wu Meirong with 25,486,560 shares, Guangzhou Fuzi Investment Management Center with 24,300,000 shares, and Wu Chunjiang with 21,778,786 shares[11] - The company's repurchase securities account holds 5,116,105 shares as of September 30, 2024[11] - The company's top 10 shareholders include China Bank - E Fund Healthcare Industry Mixed Securities Investment Fund with 5,484,884 shares and Hong Kong Securities Clearing Company with 4,505,365 shares[11] - The company's restricted shares include 18,630,000 shares held by Li Hanyong and 10,228,847 shares held by Li Handong, both under executive restrictions[12] - The company's total restricted shares amount to 34,042,876 shares, with 36,476,804 shares at the beginning of the period and 2,450,515 shares released during the period[15] Subsidiary and Investment Activities - The company's wholly-owned subsidiary obtained the registration certificate for Amlodipine Besylate Dry Suspension on January 26, 2024[17] - The wholly-owned subsidiary received the registration certificate for Oxcarbazepine Oral Suspension on May 6, 2024[17] - The wholly-owned subsidiary obtained approval for the marketing application of Eltrombopag Olamine API on June 11, 2024[17] - The wholly-owned subsidiary received the registration certificate for Argatroban Injection on June 26, 2024[18] - The wholly-owned subsidiary obtained the approval notice for Fenofibric Acid Choline Extended-Release Capsules on July 1, 2024[18] - The wholly-owned subsidiary received the registration certificate for Olmesartan Medoxomil Orally Disintegrating Tablets on July 1, 2024[18] - The company's wholly-owned subsidiary, Rui'ao Biotech, acquired a 24.05% stake in Guangzhou Rui'anbo for $10 million (approximately RMB 72.68 million), increasing its ownership to 84.75%[21] Non-Recurring Items - Non-recurring losses for Q3 2024 amounted to RMB -261.8 million, primarily due to refunds, donations, and asset disposal losses[3][4]

广东省广州市天河区珠江新城华夏路 10 号富力中心 23 楼整层及 31 楼 01、04 单元 邮编：510623 23/F, Units 01 & 04 of 31/F, R&F Center, 10 Huaxia Road, Zhujiang New Town, Tianhe District Guangzhou, Guangdong 510623, P. R. China 电话/Tel : +86 20 2826 1688 传真/Fax : +86 20 2826 1666 www.zhonglun.com 北京市中伦（广州）律师事务所 关于一品红药业股份有限公司 2024 年第三次临时股东大会的法律意见书 致：一品红药业股份有限公司 北京市中伦（广州）律师事务所（以下简称"本所"）受一品红药业股份有 限公司（以下简称"公司"）委托，指派本所律师邵芳、叶可安（以下简称"本所 律师"）出席公司 2024 年第三次临时股东大会（以下简称"本次股东大会"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市 公司股东大会规则》（以下简称"《股东大会规则》"）等有关法律、法规、规 范性文件 ...

3、本次股东大会采取现场投票与网络投票表决相结合的方式召开。 证券代码：300723 证券简称：一品红 公告编号：2024-080 一品红药业股份有限公司 2024 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无变更、否决议案的情况； 2、本次股东大会未涉及变更以往股东大会决议的情形； 一、会议召开和出席情况 （一）会议召开情况 1、会议召开的日期、时间： （1）现场会议时间：2024 年 10 月 16 日（星期三）下午 14：30 开始。 （2）网络投票时间：2024 年 10 月 16 日。 ①通过深圳证券交易所交易系统进行网络投票的时间为 2024 年 10 月 16 日交 易日上午 9：15—9：25，9：30-11：30，下午 13：00-15：00。 ②通过深圳证券交易所互联网系统投票的时间为 2024 年 10 月 16 日上午 9:15 至下午 15:00。 2、现场会议召开地点：广州市黄埔区广州国际生物岛寰宇一路 27 号云润大厦 22 层会议室。 3、会议的召开方式：本次股东大 ...

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 21.47 [3]. Core Insights - The company disclosed positive results from the Phase II clinical trial of AR882 on October 10, demonstrating superior efficacy compared to the current first-line treatment for gout, febuxostat, with a statistical significance of P<0.001 [3]. - AR882 shows good tolerability with no severe adverse reactions reported, and mild to moderate adverse reactions observed do not affect the management of patients' comorbidities [3]. - The company is expected to see a gradual recovery in traditional business disruptions while the R&D of AR882 progresses smoothly, with projected net profits for 2024-2026 estimated at -117 million, 232 million, and 347 million RMB respectively [3][7]. Summary by Sections Financial Data - The market capitalization is RMB 7,205 million, with a closing price of RMB 15.95 as of October 11 [2]. - The average daily trading volume over the past six months is RMB 73.43 million, and the 52-week price range is RMB 12.90 to RMB 31.66 [2]. Clinical Development - AR882 is expected to fill the safety gap in uric acid-lowering medications, with its Phase II results already disclosed and Phase III enrollment anticipated to start within the year [4]. - The global sales peak for AR882 is projected to exceed RMB 10 billion, with FDA fast-track designation received for the overseas Phase III trial [4]. Revenue and Profit Forecast - Revenue forecasts for 2024-2026 are adjusted to RMB 1,856 million, 2,139 million, and 2,519 million respectively, with net profit forecasts of -117 million, 232 million, and 347 million RMB [6][7]. - The company anticipates a decline in revenue for 2024 due to adjustments in the marketing system and pricing of core products, with expectations for recovery as regulatory approvals increase [5]. Valuation - The company is valued at RMB 96.97 billion, with traditional business valued at RMB 42.35 billion based on a PE ratio of 18.25x for 2025, and AR882 valued at RMB 54.62 billion using DCF methodology [9].

证券代码：300723 证券简称：一品红 公告编号：2024-079 一品红药业股份有限公司 关于 2024 年员工持股计划完成非交易过户的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、员工持股计划的基本情况 一品红药业股份有限公司（以下简称"公司"）分别于 2024 年 4 月 25 日、 2024年5月21日召开公司第三届董事会第二十二次会议和2023年度股东大会， 审议通过了《关于公司<2024 年员工持股计划（草案）>及其摘要的议案》及相关 议案。 根据《关于上市公司实施员工持股计划试点的指导意见》及《深圳证券交易 所上市公司自律监管指引第 2 号——创业板上市公司规范运作》的要求，现将公 司 2024 年员工持股计划（以下简称"本次员工持股计划"）实施进展情况公告如 下： 二、本次员工持股计划的股份来源及数量 本次员工持股计划的股票来源为公司回购专用证券账户回购的公司 A 股普 通股股票。 公司于 2021 年 5 月 10 日召开了第二届董事会第三十一次会议、第二届监事 会第二十五次会议，审议通过了《关于回购公司股份方案的议案》，同意公 ...

一品红药业股份有限公司 内部控制管理制度 第一章 总 则 第一条 为加强和规范一品红药业股份有限公司（以下简称"公司"） 内部 控制制度建设，提高公司经营管理水平和风险防范能力，保障公司经营管理的安 全性和财务信息的可靠性，健全自我约束机制，促进公司可持续发展，根据《中 国人民共和国公司法》《中华人民共和国证券法》《企业内部控制基本规范》《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《一品红药业股份有限公司章程》（以下简称 "《公司章程》"）等法律法规和规章制度的要求，结合公司的实际情况，制定本 制度。 第二条 公司内部控制是由董事会、监事会、管理层和全体员工实施的、旨 在实现控制目标的过程。公司董事会负责公司内部控制制度的制定、实施和完善， 并定期对内部控制执行情况进行全面检查和效果评估。 第三条 内部控制的目标是合理保证公司经营管理合法合规、资产安全、财 务报告及相关信息真实完整，提高经营效率和效果，促进公司实现发展战略。 第四条 公司建立与实施内部控制，应当遵循下列原则： （一）全面性原则。内部控制应当贯穿决策、执行和监督全过程，覆盖公司 ...

证券代码：300723 证券简称：一品红 公告编号：2024-074 一品红药业股份有限公司 第四届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2、审议通过《关于修订、制定公司相关治理制度的议案》 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《深圳证券交易 所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《上市公司独 立董事管理办法》等相关规定，同时结合公司实际情况，公司对相关治理制度进 一、董事会会议召开情况 一品红药业股份有限公司（以下简称"公司"）第四届董事会第三次会议于 2024 年 9 月 29 日 16:30 以现场结合通讯表决的方式召开。本次会议通知已于 2024 年 9 月 24 日以电话或电子邮件等方式向全体董事发出。会议由董事长李捍 雄先生主持，会议应到董事 5 人，实到董事 5 人。公司监事、高管列席会议。本 次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法规以及 《一品红药业股份有限公司章程》的有关规定。 二、董事会会议审议情况 1、审议通过《关于拟变更公司名称并修 ...

证券代码：300723 证券简称：一品红 公告编号：2024-076 | 公司证券代码"300723"和证券简称"一品红"保持不变。 | | --- | | | 修订前 | 修订后 | | --- | --- | --- | | 中文名称 | 一品红药业股份有限公司 | 一品红药业集团股份有限公司 | | 英文名称 | ApicHope Pharmaceutical Co.,Ltd | ApicHope Pharmaceutical Group Co.,Ltd | | 证券简称 | | 一品红（不变） | | 证券代码 | | 300723（不变） | 注：拟变更的公司名称以市场监督管理部门的最终核准结果为准。 一品红药业股份有限公司 关于拟变更公司名称并修改《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一品红药业股份有限公司（以下简称"公司"）于 2024 年 9 月 29 日召开了 第四届董事会第三次会议，审议通过了《关于拟变更公司名称并修改<公司章程> 的议案》。现将具体情况公告如下： 二、公司名称变更原因 一、公司名称变更情况 因 ...